Meeting Highlights: Anti-infectives: Resistant enterococci - a new threat A Symposium at the 19th International Conference on Chemotherapy July 16 - 21, 1995, Montreal, Canada

Autor:	Michael L Zeckel, Michael A Turik
Rok vydání:	1995
Předmět:	Pharmacology Vancomycin resistance medicine.medical_specialty business.industry Teicoplanin General Medicine biochemical phenomena metabolism and nutrition Penicillin Immunology medicine Anti infectives Vancomycin Pharmacology (medical) Intensive care medicine business medicine.drug
Zdroj:	Expert Opinion on Investigational Drugs. 4:889-891
ISSN:	1744-7658 1354-3784
DOI:	10.1517/13543784.4.9.889
Popis:	New therapeutic options are required to address the issue of Gram-positive resistance which is currently emerging. Today, the glycopeptides vancomycin and teicoplanin are the clinician's last weapons against many serious pathogens, including MRSA (methicillin-resistant S. aureus), MRSE (methicillin-resistant S. epidermidis) and penicillin- and 3rd generation cephalosporin-resistant S. pneumoniae. The development of vancomycin resistance in enterococci has many ramifications, including the possible future absence of effective therapy against a pathogen which is becoming increasingly important in nosocomial infections; and the possibility that this resistance may be transferred to other, more virulent Gram-positive organisms. This symposium was designed to address some of these issues, and the principal findings are summarised in this update.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e537c07e09afc36527fb62ca574fb402 https://doi.org/10.1517/13543784.4.9.889 Zobrazit plný text záznamu